Non-invasive Fetal Trisomy Test (Trisomy 21, 18, and 13)


BGI’s Non-Invasive Fetal Trisomy Test (NIFTY) is a superior Trisomy test for the early detection of fetal chromosomal aneuploidy; a condition in which an extra chromosome can cause mild to severe abnormalities in the fetus. Current methods of early screening such as 1st and 2nd Trimester serum screening are “non-invasive” but unreliable. The results of these tests are unreliable with both low detection rates AND high false-positive rates (which create potentially serious problems). Other test procedures, such as amniocentesis, are accurate but “invasive”; they can put the baby at risk by causing a miscarriage. BGI Health combines the latest DNA Analysis technologies (Next Generation Sequencing) with advanced data analysis (bioinformatics) to test fetal DNA for Down’s Syndrome (T21), Edwards Syndrome (T18) and Patau Syndrome (T13) without any risk to the fetus. As a result, NIFTY is both SAFE and ACCURATE making it the ideal Trisomy test.

The current “gold standard” approach to diagnose these syndromes with high accuracy and reliability is amniocentesis/CVS. However, this process is “invasive”; a large needle is inserted into an area near the fetus and sample is removed. As a result, it carries the risk of spontaneous miscarriage as well as infection. BGI’s NIFTY test is safe to the fetus and the mother, is reliable, and has an accuracy rate of 99.9%. Further, NIFTY can be performed as early as 10 weeks of gestation. This is of substantial benefit in enabling parents to make better decisions. The test is also proven. As of this time, BGI has performed more than 90,000 clinical tests in medical centers throughout the world.

Currently there are many tests performed using the mother’s blood to ensure the well-being of the fetus, such as Rh factor, antibody screening, complete blood count, Rubella (German measles) Immunity, Hepatitis B and HIV testing and more. The American Congress of Obstetricians and Gynecologists (ACOG) recommends that, in addition to these routine tests, all pregnant women should be offered prenatal testing, such as NIFTY, for detecting chromosomal abnormalities.

Whether you are a patient or a health care provider, there are many questions:

  • What is Trisomy and What Are Its Impacts?
  • Who Should Undertake Pre-Natal DNA Testing?
  • What are the Risks and Advantages of the NIFTY test versus Conventional Methods?
  • How Accurate and Reliable is the NIFTY Data?
  • How is The Test Performed?

PATIENTS: For Answers to these Questions and More Information, click here.

PROVIDERS: For More Information on NIFTY, such as Accuracy, Workflow, Turn-Around Time and more, click here.